Entry Point Capital, LLC Castle Biosciences Inc Transaction History
Entry Point Capital, LLC
- $171 Million
- Q3 2024
A detailed history of Entry Point Capital, LLC transactions in Castle Biosciences Inc stock. As of the latest transaction made, Entry Point Capital, LLC holds 9,282 shares of CSTL stock, worth $251,542. This represents 0.15% of its overall portfolio holdings.
Number of Shares
9,282Holding current value
$251,542% of portfolio
0.15%Shares
1 transactions
Others Institutions Holding CSTL
# of Institutions
201Shares Held
24.5MCall Options Held
303KPut Options Held
30.3K-
Black Rock Inc. New York, NY3.04MShares$82.5 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT1.83MShares$49.5 Million0.26% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.75MShares$47.4 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.26MShares$34.2 Million0.61% of portfolio
-
Portolan Capital Management, LLC Boston, MA1.26MShares$34 Million2.85% of portfolio
About CASTLE BIOSCIENCES INC
- Ticker CSTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 26,297,000
- Market Cap $713M
- Description
- Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...